Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

63%

5 of 8 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2
4(57.1%)
Phase 1
3(42.9%)
7Total
Phase 2(4)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT02358369Phase 2Completed

Dose-Ranging Study of the Bimatoprost Ocular Insert

Role: lead

NCT02537015Phase 2Completed

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

Role: lead

NCT02143843Phase 2Completed

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

Role: lead

NCT02742649Phase 1Completed

A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension

Role: lead

NCT01915940Phase 2Completed

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

Role: lead

NCT02384772Completed

Survey of Patients Taking IOP-Lowering Eye Drops

Role: lead

NCT02444767Phase 1Completed

Bimatoprost Ocular Insert Pharmacokinetic Study

Role: lead

NCT01943721Phase 1Completed

A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension

Role: lead

All 8 trials loaded